Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Conduent Non-GAAP EPS of -$0.09 misses by $0.07, revenue of $770M misses by $20.5M (SeekingAlpha) +++ CONDUENT Aktie -3,90%

WEST PHARMACEUTICAL Aktie

 >WEST PHARMA Aktienkurs 
211.45 EUR    (TradegateBSX)
Ask: 213.9 EUR / 16 Stück
Bid: 209 EUR / 16 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
WEST PHARMA Aktie über LYNX handeln
>WEST PHARMA Performance
1 Woche: +4,7%
1 Monat: -12,1%
3 Monate: -10,9%
6 Monate: -0,8%
1 Jahr: -32,3%
laufendes Jahr: -10,3%
>WEST PHARMACEUTICAL Aktie
Name:  WEST PHARMACEUTICAL SERVICES
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US9553061055 / 864330
Symbol/ Ticker:  WPS (Frankfurt) / WST (NYSE)
Kürzel:  FRA:WPS, ETR:WPS, WPS:GR, NYSE:WST
Index:  S&P500
Webseite:  https://www.westpharma.co..
Profil:  West Pharmaceutical Services, Inc. is a leading pr..
>Volltext..
Marktkapitalisierung:  15050.17 Mio. EUR
Unternehmenswert:  14772.45 Mio. EUR
Umsatz:  2535.58 Mio. EUR
EBITDA:  668.94 Mio. EUR
Nettogewinn:  413.21 Mio. EUR
Gewinn je Aktie:  5.71 EUR
Schulden:  254.63 Mio. EUR
Liquide Mittel:  528.18 Mio. EUR
Operativer Cashflow:  583.05 Mio. EUR
Bargeldquote:  0.99
Umsatzwachstum:  -0.47%
Gewinnwachstum:  -6.62%
Dividende je Aktie:  0.73 EUR
Dividendenrendite:  0.35%
Dividendenschätzung:  0.35%
Div. Historie:  28.01.26 - 0.184118€
12.11.25 - 0.18900199€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  WEST PHARMACEUTICAL, WEST PHARMA, WEST PHARMACEUTICALS
Letzte Datenerhebung:  12.02.26
>WEST PHARMA Kennzahlen
Aktien/ Unternehmen:
Aktien: 71.94 Mio. St.
Frei handelbar: 99.38%
Rückkaufquote: 0.96%
Mitarbeiter: 10600
Umsatz/Mitarb.: 0.23 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 37.64%
Bewertung:
KGV: 35.79
KGV lG: 34.08
KUV: 5.61
KBV: 5.69
PEG-Ratio: 237.56
EV/EBITDA: 22.08
Rentabilität:
Bruttomarge: 35.59%
Gewinnmarge: 16.3%
Operative Marge: 20.91%
Managementeffizenz:
Gesamtkaprendite: 12.64%
Eigenkaprendite: 16.94%
>WEST PHARMA Peer Group
Gesundheit
 
12.02.26 - 12:54
West Pharmaceutical Q4 Earnings Rise; Guides FY26 (AFX)
 
WASHINGTON (dpa-AFX) - West Pharmaceutical Services, Inc. (WST), on Thursday, reported its higher net income in the fourth quarter compared with the previous year and issued an outlook for the ful......
12.02.26 - 12:30
West Pharmaceutical Services Inc. Q4 Income Rises (AFX)
 
WASHINGTON (dpa-AFX) - West Pharmaceutical Services Inc. (WST) released a profit for its fourth quarter that Increases, from the same period last yearThe company's bottom line came in at $132.1 mi......
12.02.26 - 12:06
West Pharmaceutical beats Q4 street views, gives FY outlook (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.02.26 - 12:03
West Reports Fourth-Quarter and Full-Year 2025 Results (PR Newswire)
 
– Strong 4Q results, driven by double-digit organic revenue growth in HVP Components – – Introduces Fiscal 2026 Financial Guidance – EXTON, Pa., Feb. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable......
09.02.26 - 18:15
WST Q4 Earnings Preview: Can HVP Momentum Continue to Drive Margins? (Zacks)
 
West Pharmaceutical heads into Q4 with HVP demand likely lifting margins, but tariff risk looms as revenue and EPS targets come into focus....
30.01.26 - 17:30
Here′s Why West Pharmaceutical (WST) Is a Great ′Buy the Bottom′ Stock Now (Zacks)
 
West Pharmaceutical (WST) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term....
29.01.26 - 12:06
West to Host Fourth-Quarter and Full-Year 2025 Conference Call (PR Newswire)
 
EXTON, Pa., Jan. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2025 financial results before the market opens on......
23.01.26 - 21:15
WST Launches Synchrony S1 Prefillable Syringe at Pharmapack (Zacks)
 
West Pharmaceutical debuts the Synchrony S1 prefillable syringe at Pharmapack 2026, enhancing biologics, vaccines and home-care support....
23.01.26 - 11:30
Zacks Industry Outlook Highlights McKesson, Cardinal Health, West Pharmaceutical and Align Technology (Zacks)
 
McKesson, Cardinal Health, West Pharmaceutical, and Align Technology are set to benefit from innovation, aging populations, and rising medical supply demand in 2026....
22.01.26 - 19:45
All You Need to Know About West Pharmaceutical (WST) Rating Upgrade to Strong Buy (Zacks)
 
West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....
21.01.26 - 16:45
After Plunging 9.7% in 4 Weeks, Here′s Why the Trend Might Reverse for West Pharmaceutical (WST) (Zacks)
 
The heavy selling pressure might have exhausted for West Pharmaceutical (WST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal....
20.01.26 - 12:01
West Synchrony™ S1 Prefillable Syringe System Commercially Available at Pharmapack (PR Newswire)
 
Showcasing Leadership in Drug Delivery Solutions and Approaches to Combination Products EXTON, Pa., Jan. 20, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced participation at......
15.01.26 - 14:24
Earnings Preview: What to Expect From West Pharmaceutical Services' Report (Barchart)
 
Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...
14.01.26 - 20:30
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now (Zacks)
 
WST is riding on surging GLP-1 demand and HVP expansion. Yet, pricing pressure, tariff risks and contract manufacturing headwinds cloud the near-term outlook....
13.01.26 - 17:30
Wall Street Analysts See a 26.42% Upside in West Pharmaceutical (WST): Can the Stock Really Move This High? (Zacks)
 
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in West Pharmaceutical (WST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock....
12.01.26 - 12:48
West To Sell SmartDose 3.5mL On-Body Delivery System To AbbVie For $112.5 Mln (AFX)
 
WASHINGTON (dpa-AFX) - West Pharmaceutical Services, Inc. (WST) on Monday said it has agreed to sell all manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System, along with......
12.01.26 - 12:15
AbbVie to buy Arizona manufacturing facility from West Pharmaceutical (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.01.26 - 12:03
West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie (PR Newswire)
 
EXTON, Pa., Jan. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the company has reached a definitive agreement to sell all manufacturing and supply rights for......
06.01.26 - 11:09
West Pharmaceutical Services Aktie: Wachstum des Marktes für Abnehmspritzen und andere Faktoren beflügeln das Geschäft (Aktiencheck)
 
Paris (www.aktiencheck.de) - West Pharmaceutical Services-Aktienanalyse von BNP Paribas: Egmond Haidt von BNP Paribas nimmt die Aktie von West Pharmaceutical Services Inc. (ISIN: US9553061055, WKN: 864330, Ticker-Symbol: WPS, NYSE-Symbol: WST) unter die Lupe. West Pharmaceutical Services sei viele Jahre bei Investoren als Unternehmen mit deutlichem Umsatz- und Gewinnwachstum bekannt gewesen. [mehr]...
17.12.25 - 17:42
West Pharmaceutical Services Stock: Is WST Underperforming the Healthcare Sector? (Barchart)
 
Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Mag alles Leid und Schatten sein - doch diese süße Sonnenstunde nicht, und nicht der Duft vom roten Klee, und nicht das tiefe, zarte Wohlgefühl in meiner Seele. - Hermann Hesse
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!